Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73rd Annual Scientific Session (ACC.24) taking place in Atlanta, GA from April 6, 2024 – April 8, 2024.

Title: 1075-11 – Efficacy and Safety of Aficamten in the First Cohort of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Completing 1-Year Follow-Up: Findings From the FOREST-HCM Study
Presenter: Sara Saberi, M.D., M.S., Associate Professor of Internal Medicine, University of Michigan Health Frankel Cardiovascular Center
Session: 1075 – Bulking Up: Advances in Hypertrophic Cardiomyopathy
Date: April 7, 2024
Presentation Time: 2:00 PM-2:10 PM Eastern Time
Location: Moderated Poster Theater 03

Title: 1226-128 – Association Between Beta Blocker Use and Incidence of New Atrial Fibrillation and Flutter Post-Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy
Presenter: Morris M. Kim, M.D., Cardiovascular Disease Fellow, Oregon Health & Science University
Session: 1226 – Heart Failure and Cardiomyopathies: Special Populations 02
Date: April 6, 2024
Presentation Time: 10:45 AM-11:30 AM Eastern Time
Location: Hall B4-5

Title: 1343-122 – Standard of Care Medication Patterns of Use Before and After Septal Myectomy in Patients with Obstructive Hypertrophic Cardiomyopathy
Presenter: Tristan B. Post, M.D., Clinical Research Coordinator, Oregon Health & Science University
Session: 1343 – Heart Failure and Cardiomyopathies: Pharmacology 08
Date: April 7, 2024
Presentation Time: 9:15 AM-10:00 AM Eastern Time
Location: Hall B4-5

Title: 1075-03 – Racial and Ethnic Differences in Cardiovascular Outcomes in Patients Diagnosed with Hypertrophic Cardiomyopathy
Presenter: Nosheen Reza, M.D., Assistant Professor of Medicine, Perelman School of Medicine at the University of Pennsylvania
Session: 1075 – Bulking Up: Advances in Hypertrophic Cardiomyopathy
Date: April 7, 2024
Presentation Time: 1:00 PM-1:10 PM Eastern Time
Location: Moderated Poster Theater 03

About Cytokinetics

Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in two ongoing Phase 3 clinical trials: MAPLE-HCM, evaluating aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM and ACACIA-HCM, evaluating aficamten in patients with non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility.

For additional information about Cytokinetics, visit and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlined in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

error: Content is protected !!